美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

三倍做多標普生物-Direxion

261.30

-4.7000-1.77%

盤前：264.002.70+1.03%06:49 EDT

成交量：22.74萬

成交額：6,097.03萬

市值：5.16億

市盈率：- -

高：278.96

開：273.29

低：261.30

收：266.00

52周最高：341.93

52周最低：74.95

股本：197.45萬

流通股本：197.45萬

量比：0.94

換手率：11.52%

股息：1.02

股息率：0.39%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞公告

中國FAP靶向實體瘤診斷核藥首次獲FDA快速通道資格認定，遠大醫藥(00512)自研產品直擊泛實體瘤千億美元未滿足市場需求

遠大醫藥(00512.HK)自主研發的重磅全球創新放射性核素偶聯藥物GPN01530-2 獲得FDA授予的快速通道資格

遠大醫藥(00512)自主研發的重磅全球創新放射性核素偶聯藥物GPN01530-2 獲得FDA授予的快速通道資格

醫療保健板塊動態：市場快訊匯總

人民健康保險天津分公司被罰28萬，涉欺騙投保人

梁振英：在醫療健康領域香港也可成為「超級聯繫人」

醫療保健板塊市場快訊

醫療健康板塊綜述：市場動態快報

人保健康天津分公司因欺騙投保人被罰28萬元一人被終身禁業

ELANCO公司的新世界螺旋蠅藥物獲得FDA緊急批准。

胡偉獲批擔任人保健康董事

和諧健康保險孝感中支被罰18萬，涉編制虛假資料

醫療保健板塊市場快訊匯總

把腫瘤變成「原位疫苗」!Replimune(REPL.US)溶瘤病毒闖過FDA，PD-1耐藥黑色素瘤迎來新一代免疫重啓方案

北京經濟技術開發區：鼓勵具身智能、自動駕駛、醫療健康等重點領域數據交易流通每年發放1億元數據券

醫療保健板塊市場動態綜述

醫療板塊市場動態速覽

構建社保商保分層協同機制，破解創新藥支付困境——商業醫療保險與創新藥支付管理研討會在京召開

Moderna研發的首款mRNA流感疫苗獲FDA批准

莫德納首款mRNA流感疫苗獲FDA批准

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/hant/stock/LABU/news?page=9"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"LABU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","market":"US","secType":"STK","nameCN":"三倍做多標普生物-Direxion","latestPrice":261.3,"timestamp":1789156800000,"preClose":266,"halted":0,"volume":227375,"hourTrading":{"tag":"盘前","latestPrice":264,"preClose":261.3,"latestTime":"06:49 EDT","volume":485,"amount":127722.53355000001,"timestamp":1789382946044,"change":2.7,"changeRate":0.010333,"amplitude":0.011251},"delay":0,"changeRate":-0.017669172932330786,"floatShares":1974486,"shares":1974486,"eps":0,"marketStatus":"盤前交易","change":-4.7,"latestTime":"09-14 06:49:24 EDT","open":273.29,"high":278.9613,"low":261.3,"amount":60970299.293749996,"amplitude":0.066396,"askPrice":268,"askSize":200,"bidPrice":261.2,"bidSize":200,"shortable":3,"etf":3,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1789392600000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":261.3,"sharesOutstanding":3074486,"nav":261.603,"aum":516531253.77,"dividendRate":0.0039,"bidAskSpread":0.003144,"preHourTrading":{"tag":"盘前","latestPrice":264,"preClose":261.3,"latestTime":"06:49 EDT","volume":485,"amount":127722.53355000001,"timestamp":1789382946044,"change":2.7,"changeRate":0.010333,"amplitude":0.011251},"postHourTrading":{"tag":"盘后","latestPrice":261.3,"preClose":261.3,"latestTime":"19:58 EDT","volume":728,"amount":191085.6107,"timestamp":1789171090575,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.9397711565267511,"impliedVol":0.8728,"impliedVolPercentile":0.324},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","floatShares":1974486,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.9397711565267511,"shares":1974486,"dividePrice":1.0191,"high":278.9613,"amplitude":0.066396,"preClose":266,"low":261.3,"week52Low":74.95,"pbRate":"--","week52High":341.93,"institutionHeld":0,"latestPrice":261.3,"eps":0,"divideRate":0.0039,"volume":227375,"delay":0,"ttmEps":0,"open":273.29,"prevYearClose":159.39,"prevWeekClose":261.3,"prevMonthClose":296.31,"prevQuarterClose":292.1,"fiveDayClose":305.86,"twentyDayClose":273.91,"sixtyDayClose":184.63},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LABU\",params:#limit:5,,,undefined,":[{"date":"2025-09-23","symbol":"LABU","amount":0.10273,"announcedDate":"2025-09-22","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-23","defaultRemindTime":1758634200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-30","payableDate":"2025-09-23","currency":"USD","dateTimestamp":1758600000000,"payDate":"2025-09-30"},{"date":"2025-06-24","symbol":"LABU","amount":0.21897,"announcedDate":"2025-06-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-24","defaultRemindTime":1750771800000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-01","payableDate":"2025-06-24","currency":"USD","dateTimestamp":1750737600000,"payDate":"2025-07-01"},{"date":"2025-03-25","symbol":"LABU","amount":0.10714,"announcedDate":"2025-03-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-25","defaultRemindTime":1742909400000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-01","payableDate":"2025-03-25","currency":"USD","dateTimestamp":1742875200000,"payDate":"2025-04-01"},{"date":"2024-06-25","symbol":"LABU","amount":0.15021,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-25","defaultRemindTime":1719322200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-07-02","payableDate":"2024-06-25","currency":"USD","dateTimestamp":1719288000000,"payDate":"2024-07-02"},{"date":"2024-03-19","symbol":"LABU","amount":0.16064,"announcedDate":"2024-03-18","type":"dividend","market":"US","newRecordDate":"2024-03-20","defaultRemindTime":1710855000000,"name":"三倍做多标普生物-Direxion","recordDate":"2024-03-26","payableDate":"2024-03-20","currency":"USD","dateTimestamp":1710820800000,"payDate":"2024-03-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LABU\",market:\"US\",,,undefined,":[{"executeDate":"2018-06-19","recordDate":"2018-06-20","paymentDate":"2018-06-26","value":0.01932,"currency":"USD"},{"executeDate":"2018-09-25","recordDate":"2018-09-26","paymentDate":"2018-10-02","value":0.0954,"currency":"USD"},{"executeDate":"2018-12-27","recordDate":"2018-12-28","paymentDate":"2019-01-04","value":0.09621,"currency":"USD"},{"executeDate":"2019-03-19","recordDate":"2019-03-20","paymentDate":"2019-03-26","value":0.10973,"currency":"USD"},{"executeDate":"2019-06-25","recordDate":"2019-06-26","paymentDate":"2019-07-02","value":0.03745,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LABU\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LABU\",pageSize:20,pageCount:9,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2658728656","title":"中國FAP靶向實體瘤診斷核藥首次獲FDA快速通道資格認定，遠大醫藥(00512)自研產品直擊泛實體瘤千億美元未滿足市場需求","url":"https://stock-news.laohu8.com/highlight/detail?id=2658728656","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658728656?lang=zh_tw&edition=fundamental","pubTime":"2026-08-09 18:18","pubTimestamp":1786270729,"startTime":"0","endTime":"0","summary":"作为核药龙头企业，远大医药近日在该领域再次取得重磅突破，公司FAP靶点创新核药GPN01530-2已获得美国FDA授予快速通道资格，成为全球首个获得FDA快速通道认定的实体瘤FAP靶点诊断核药。据悉，GPN01530-2此前已获FDA批准开展用于诊断实体瘤的I/II期临床研究，此次其获快速通道资格认定，标志着美国监管机构认可该产品在实体瘤诊断的重要潜力，有望加快GPN01530-2未来开发及上市进程，尽早惠及全球患者。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477702.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00512","BK4585","BK1191","BK4588","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658367401","title":"遠大醫藥(00512.HK)自主研發的重磅全球創新放射性核素偶聯藥物GPN01530-2 獲得FDA授予的快速通道資格","url":"https://stock-news.laohu8.com/highlight/detail?id=2658367401","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658367401?lang=zh_tw&edition=fundamental","pubTime":"2026-08-09 18:10","pubTimestamp":1786270215,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4588","LABU","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658018674","title":"遠大醫藥(00512)自主研發的重磅全球創新放射性核素偶聯藥物GPN01530-2 獲得FDA授予的快速通道資格","url":"https://stock-news.laohu8.com/highlight/detail?id=2658018674","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658018674?lang=zh_tw&edition=fundamental","pubTime":"2026-08-09 18:10","pubTimestamp":1786270215,"startTime":"0","endTime":"0","summary":"智通财经APP讯，远大医药 发布公告，集团自主研发的用于诊断实体瘤的全球创新放射性核素偶联药物  GPN01530-2 近日获得美国食品药品监督管理局授予的快速通道资格。GPN01530-2特异性靶向FAP为多种恶性肿瘤的诊断提供了新的可能。集团自主研发的GPN01530-2 优化了 FAP 配体的结构，提高了其在肿瘤组织中的摄取，同时降低其在正常组织中的摄取。据统计，全球放射性药物市场规模自2018年的50亿美元增至2024年的97亿美元，复合年增长率达 11.7%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477698.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LABU","BK1593","BK1583","BK4585","HK0000165453.HKD","BK1191","BK4588","00512","BK1161","01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131279132","title":"醫療保健板塊動態：市場快訊匯總","url":"https://stock-news.laohu8.com/highlight/detail?id=1131279132","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131279132?lang=zh_tw&edition=fundamental","pubTime":"2026-08-08 16:22","pubTimestamp":1786177346,"startTime":"0","endTime":"0","summary":"这些内容独家发布于道琼斯新闻社，分别在美东时间4:20、12:20和16:50。赛诺菲股价上涨2%，再生元股价则基本持平。第二季度调整后营业利润超出预期16%，主要得益于20亿丹麦克朗的回扣调整。该药企Wegovy药片的销售额略低于市场共识，而其美国注射剂销量则低于预期9%。花旗补充称，全年业绩指引上调已在预期之内，而CagriSema在与礼来替尔泊肽的头对头试验中失败，进一步打击了市场信心。该股上涨4.7%，报307.38克朗。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","XLV","BK4588","BK4585","BK4581","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657276226","title":"人民健康保險天津分公司被罰28萬，涉欺騙投保人","url":"https://stock-news.laohu8.com/highlight/detail?id=2657276226","media":"蓝鲸财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657276226?lang=zh_tw&edition=fundamental","pubTime":"2026-08-08 14:22","pubTimestamp":1786170134,"startTime":"0","endTime":"0","summary":"蓝鲸新闻8月8日讯，近日，国家金融监督管理总局天津监管局发布行政处罚决定书，剑指中国人民健康保险股份有限公司天津分公司及相关责任人。罚单显示，中国人民健康保险股份有限公司天津分公司的主要违法违规行为是：欺骗投保人。针对上述违法行为，国家金融监督管理总局天津监管局对中国人民健康保险股份有限公司天津分公司罚款28万元；对闻伟禁止终身进入保险业。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1786167414374667463","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["LABU","BK4581","XLV","BK4585","XBI","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657627583","title":"梁振英：在醫療健康領域香港也可成為「超級聯繫人」","url":"https://stock-news.laohu8.com/highlight/detail?id=2657627583","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657627583?lang=zh_tw&edition=fundamental","pubTime":"2026-08-08 13:17","pubTimestamp":1786166220,"startTime":"0","endTime":"0","summary":"梁振英表示，香港的价值定位是作为内地与其他国家之间的“超级联系人”。梁振英指出，如果把这套逻辑推演到医疗健康领域，未来香港完全有机会充当连接角色，搭建双向桥梁，对接全球供给与中国需求，同时对接中国供给与全球需求，这并非空想，而是长期目标，目前才刚刚起步。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-08-08/doc-inimqptv6574030.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4581","LABU","XLV","VHT","BK4550","BK4585","XBI","BK4588","159760","IXJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183021512","title":"醫療保健板塊市場快訊","url":"https://stock-news.laohu8.com/highlight/detail?id=1183021512","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183021512?lang=zh_tw&edition=fundamental","pubTime":"2026-08-08 04:55","pubTimestamp":1786136134,"startTime":"0","endTime":"0","summary":"她认为该交易按当前方案完成的可能性为75%，但鉴于Jamieson的“优质资产”属性、在加拿大的领先市场份额，以及预计至2028年收入复合年增长率达11%，存在25%的可能性出现更高报价。消息公布后，TD将目标股价从48加元上调至49加元，以反映概率加权结果，但将评级从“买入”下调至“持有”。该股盘中上涨9.6%，报45.47加元。** 欧洲斯托克600指数上涨0.2%，软件和医疗保健板块领涨。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XLV","XBI","BK4581","LABU","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145080185","title":"醫療健康板塊綜述：市場動態快報","url":"https://stock-news.laohu8.com/highlight/detail?id=1145080185","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145080185?lang=zh_tw&edition=fundamental","pubTime":"2026-08-08 00:23","pubTimestamp":1786119809,"startTime":"0","endTime":"0","summary":"她在报告中坦言，“对报价未达预期感到惊讶”。该分析师认为，按当前方案完成交易的概率为75%，但同时存在25%的可能性，因Jamieson具备“优质资产”属性、在加拿大市场占据领先份额，且预计至2028年收入复合年增长率达11%，报价有望被上调。消息公布后，TD将目标股价从48加元上调至49加元，以反映概率加权结果，同时将评级从“买入”下调至“持有”。该股现涨9.6%，报45.47加元。泛欧斯托克600指数上涨0.2%，软件与医疗健康板块领涨。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","BK4585","BK4581","BK4588","XLV","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657649773","title":"人保健康天津分公司因欺騙投保人被罰28萬元 一人被終身禁業","url":"https://stock-news.laohu8.com/highlight/detail?id=2657649773","media":"金融一线","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657649773?lang=zh_tw&edition=fundamental","pubTime":"2026-08-07 21:36","pubTimestamp":1786109760,"startTime":"0","endTime":"0","summary":"8月7日金融一线消息，国家金融监督管理总局天津监管局行政处罚信息公开表显示，中国人民健康保险股份有限公司天津分公司因欺骗投保人，被罚款28万元。闻伟被禁止终身进入保险业。序号当事人名称主要违法违规行为行政处罚内容作出决定机关1中国人民健康保险股份有限公司天津分公司欺骗投保人。对中国人民健康保险股份有限公司天津分公司罚款28万元；对闻伟禁止终身进入保险业国家金融监督管理总局天津监管局","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jryx/fd/2026-08-07/doc-inimnzse9955329.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["XLV","XBI","BK4588","LABU","BK4585","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657646475","title":"ELANCO公司的新世界螺旋蠅藥物獲得FDA緊急批准。","url":"https://stock-news.laohu8.com/highlight/detail?id=2657646475","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657646475?lang=zh_tw&edition=fundamental","pubTime":"2026-08-07 21:03","pubTimestamp":1786107806,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4588","LABU","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657643444","title":"胡偉獲批擔任人保健康董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2657643444","media":"金融一线","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657643444?lang=zh_tw&edition=fundamental","pubTime":"2026-08-07 20:09","pubTimestamp":1786104540,"startTime":"0","endTime":"0","summary":"8月7日金融一线消息，国家金融监督管理总局发布《关于胡伟中国人民健康保险股份有限公司董事任职资格的批复》，核准胡伟中国人民健康保险股份有限公司董事的任职资格。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jryx/hm/2026-08-07/doc-inimnzsm4704005.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["XLV","XBI","BK4585","BK4581","LABU","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657617229","title":"和諧健康保險孝感中支被罰18萬，涉編制虛假資料","url":"https://stock-news.laohu8.com/highlight/detail?id=2657617229","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657617229?lang=zh_tw&edition=fundamental","pubTime":"2026-08-07 18:58","pubTimestamp":1786100322,"startTime":"0","endTime":"0","summary":"蓝鲸新闻8月7日讯，近日，孝感金融监管分局发布行政处罚决定书，剑指和谐健康保险股份有限公司孝感中心支公司及相关责任人。罚单显示，和谐健康保险股份有限公司孝感中心支公司的主要违法违规行为是：编制虚假资料。针对上述违法行为，孝感金融监管分局对和谐健康保险股份有限公司孝感中心支公司罚款18万元，对李婷警告并罚款2.5万元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1786096518804106658","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK4585","LABU","XLV","XBI","BK4581","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129560773","title":"醫療保健板塊市場快訊匯總","url":"https://stock-news.laohu8.com/highlight/detail?id=1129560773","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1129560773?lang=zh_tw&edition=fundamental","pubTime":"2026-08-07 16:22","pubTimestamp":1786090970,"startTime":"0","endTime":"0","summary":"投资者在美国就业数据和中东局势谈判消息出炉前保持观望态度。泛欧斯托克600指数微涨0.2%，软件与医疗保健板块领涨。伦敦富时100指数同样小幅上扬0.2%，国际油价企稳带动石油巨头走强。帝亚吉欧延续涨势，股价已连续第二个交易日攀升，目前涨幅达1.5%。软件巨头SAP攀升3.5%，但戴姆勒卡车控股公司在发布财报后下跌2.9%。意大利富时MIB指数基本持平，而西班牙IBEX 35指数因银行股走弱而微跌0.3%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XBI","BK4588","BK4581","XLV","BK4585","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657904156","title":"把腫瘤變成「原位疫苗」!Replimune(REPL.US)溶瘤病毒闖過FDA，PD-1耐藥黑色素瘤迎來新一代免疫重啓方案","url":"https://stock-news.laohu8.com/highlight/detail?id=2657904156","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657904156?lang=zh_tw&edition=fundamental","pubTime":"2026-08-07 14:59","pubTimestamp":1786085956,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1169589451.USD","BK4585","LU1169590202.USD","REPL","LABU","PD","BK4139","BK4023","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657965566","title":"北京經濟技術開發區：鼓勵具身智能、自動駕駛、醫療健康等重點領域數據交易流通 每年發放1億元數據券","url":"https://stock-news.laohu8.com/highlight/detail?id=2657965566","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657965566?lang=zh_tw&edition=fundamental","pubTime":"2026-08-07 12:34","pubTimestamp":1786077245,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4550","TARK","IXJ","HAIL","XT","KOMP","MOTO","BK4585","VHT","XBI","FAI","CARZ","IDRV","BK4581","LABU","NBDS","FDIF","XLV","BK4588","DRIV","WDRN","ROBT","IQM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160721676","title":"醫療保健板塊市場動態綜述","url":"https://stock-news.laohu8.com/highlight/detail?id=1160721676","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160721676?lang=zh_tw&edition=fundamental","pubTime":"2026-08-07 00:25","pubTimestamp":1786033543,"startTime":"0","endTime":"0","summary":"0739 ET - 伦敦上市制药商Hikma Pharmaceuticals上半年业绩表现强劲，但其对全年业绩的展望却显得颇为保守，并未随之上调，这令市场感到意外。这一积极表现主要得益于Hikma旗下品牌药部门的强劲增长，预计将受到投资者的欢迎。然而，即便上半年核心运营利润率大幅改善，Hikma仍坚持其2026年全年核心运营利润指引，即7.2亿至7.7亿美元，这一区间与市场普遍预期的7.31亿美元相比，并未显得更为乐观。受此消息影响，公司股价大涨10%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XBI","BK4585","BK4581","XLV","BK4588","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137064261","title":"醫療板塊市場動態速覽","url":"https://stock-news.laohu8.com/highlight/detail?id=1137064261","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137064261?lang=zh_tw&edition=fundamental","pubTime":"2026-08-06 16:26","pubTimestamp":1786004808,"startTime":"0","endTime":"0","summary":"1655 GMT - 礼来公司CEO David Ricks在CNBC上表示，该公司近期推出的每日一次GLP-1口服药Foundayo，尽管定价更低，但正在扩大市场而非蚕食现有市场。与此同时，减肥治疗的覆盖面持续扩大，进一步拓宽了潜在市场总规模。这些利好因素增强了礼来公司的信心，使其将营收预期从820亿至850亿美元上调至850亿至870亿美元。礼来股价目前上涨3%。市场对GLP-1减肥药的持续强劲需求推动第二季度营收跃升48%，达到229.7亿美元，超出预期的206.9亿美元。诺和诺德股价下跌4%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LABU","XBI","BK4581","XLV","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657669688","title":"構建社保商保分層協同機制，破解創新藥支付困境——商業醫療保險與創新藥支付管理研討會在京召開","url":"https://stock-news.laohu8.com/highlight/detail?id=2657669688","media":"金融一线","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657669688?lang=zh_tw&edition=fundamental","pubTime":"2026-08-06 14:55","pubTimestamp":1785999300,"startTime":"0","endTime":"0","summary":"专题：新浪健康保险研究院2026年7月31日，由中央财经大学保险学院主办、新浪健康保险研究院协办的“商业医疗保险与创新药支付管理研讨会”在京举行。因此，在医保基金收支承压、商业保险资金池有限、天价药风险集中的现实约束下，造成创新药支付困境凸显。商保在创新药上市早期的支付补充价值。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/insurance/bxyy/2026-08-06/doc-inimkfvm3890828.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["XLV","BK4585","XBI","06978","LNGR","159992","BK4588","BK1574","BK1161","IBBQ","LABU","MEDX","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657232501","title":"Moderna研發的首款mRNA流感疫苗獲FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2657232501","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657232501?lang=zh_tw&edition=fundamental","pubTime":"2026-08-06 13:20","pubTimestamp":1785993606,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4588","LABU","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657917506","title":"莫德納首款mRNA流感疫苗獲FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2657917506","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657917506?lang=zh_tw&edition=fundamental","pubTime":"2026-08-06 11:44","pubTimestamp":1785987861,"startTime":"0","endTime":"0","summary":"来源：环球市场播报美国食品药品管理局批准了莫德纳针对50岁及以上成人的mRNA流感疫苗。这款名为mFlusiva的疫苗采用了与莫德纳新冠疫苗相同的mRNA技术。今年2月，FDA最初直接拒绝审查莫德纳的申请。莫德纳对FDA 2月份的决定感到意外。几天后，莫德纳提出了一份包含另一项试验的修订计划，FDA随后改变了立场。即使获得FDA批准，该疫苗的商业前景依然存在不确定性。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2026/08/06114458030151.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["BK4588","LABU","BK4585"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":9,"totalSize":200,"code":"91000000","status":"200"}]}}